NMDP-BTM_Dual_2_Color_BlueGreen_Logo_RGB_2000x542 (1).png
Sickle Cell Warrior Program from The National Marrow Donor Program® (NMDP)/Be The Match® Expands Access to Bone Marrow Transplant as a Curative Treatment
August 31, 2023 09:00 ET | Be The Match
During Sickle Cell Awareness Month, NMPD/Be The Match reminds individuals to visit SickleCellConnect.com to access essential resources, learn more about Sickle Cell Disease, and join the Be The Match...
NMDP-BTM_Dual_2_Color_BlueGreen_Logo_RGB_2000x542 (1).png
Be The Match® Celebrates One Thousand “Get in the Game” Life-Saving Donors!
June 06, 2023 08:00 ET | Be The Match
MINNEAPOLIS, June 06, 2023 (GLOBE NEWSWIRE) -- Be The Match®, a global leader working to save lives through cellular therapy, today celebrates 1,000 blood stem cell or marrow donors through the “Get...
Featured Image for Experimental Biology and Medicine
Pain Intensity in Sickle Cell Disease
November 14, 2022 10:00 ET | Experimental Biology and Medicine
WASHINGTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 247, Issue 17, September, 2022) improves our understanding of pain phenotypes...
Inserting Hb Variant cartridge
Hemex Health announces breakthrough measurement capability for clinicians monitoring sickle cell disease therapy
May 08, 2022 06:00 ET | Hemex Health
PORTLAND, Ore. and MUMBAI, India, May 08, 2022 (GLOBE NEWSWIRE) -- Hemex Health, a Portland, Oregon-based health-tech startup, announced a significant enhancement to their Gazelle™ Hb Variant test,...
6th Leadership Summit - Sickle Cell Consortium
Sickle Cell Consortium Hosts 6th Annual Leadership Summit - Advocacy & Capacity-Building in the Digital Age
April 25, 2022 08:00 ET | Sickle Cell Consortium
ATLANTA, April 25, 2022 (GLOBE NEWSWIRE) -- The Sickle Cell Consortium hosts the 6th Annual Leadership Summit and General Assembly of Patients, Caregivers, and Community-Based Organizations (CBOs)...
Imara-Logo-Color-RGB.jpg
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
April 05, 2022 06:45 ET | Imara, Inc.
Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat...
Imara-Logo-Color-RGB.jpg
Imara Reports Full Year 2021 Financial Results and Business Highlights
March 15, 2022 07:00 ET | Imara, Inc.
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
March 08, 2022 07:00 ET | Imara, Inc.
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 07:00 ET | Imara, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 05, 2022 07:00 ET | Imara, Inc.
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...